FT Biotechnology 51 F RE (F00001634E)
9.534
+0.05 (+0.48%)
USD |
May 20 2022
Returns Chart
Key Stats
Customize
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| 0.22% | -- | 0.00% | -- |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| -- | -9.64% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Trust consists of a portfolio of common stocks. The Trust seeks above- average capital appreciation. The Trust is concentrated in stocks of the industry or group of industries comprising the health care sector. |
| General | |
| Security Type | Unit Investment Trust |
| Oldest Share Symbol | F00001634C |
| Equity Style | Mid Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | First Trust Portfolios L.P. |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
--
-3.360B
Category Low
9.492B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
Date Unavailable
Performance Versus Category
As of May 20, 2022. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of May 20, 2022.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| AbbVie Inc | 6.10% | 151.01 | -0.47% |
| Moderna Inc | 5.90% | 136.25 | -4.97% |
| United Therapeutics Corp | 5.36% | 188.33 | 1.08% |
| Regeneron Pharmaceuticals Inc | 5.13% | 661.14 | 0.61% |
| Thermo Fisher Scientific Inc | 4.82% | 555.15 | 0.80% |
| Bio-Techne Corp | 4.79% | 366.35 | -0.02% |
| Vertex Pharmaceuticals Inc | 4.77% | 258.59 | 1.23% |
| IQVIA Holdings Inc | 4.61% | 201.83 | 0.04% |
| Avantor Inc | 4.52% | 31.22 | 0.35% |
| AstraZeneca PLC ADR | 4.41% | 66.21 | 2.59% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | -- |
| Administration Fee | -- |
| Performance Fee | -- |
| Switching Fee | -- |
| Transaction Fee | -- |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
Basic Info
| Investment Strategy | |
| The Trust consists of a portfolio of common stocks. The Trust seeks above- average capital appreciation. The Trust is concentrated in stocks of the industry or group of industries comprising the health care sector. |
| General | |
| Security Type | Unit Investment Trust |
| Oldest Share Symbol | F00001634C |
| Equity Style | Mid Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | First Trust Portfolios L.P. |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (5-20-22) | 0.00% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 18.84 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of May 18, 2022
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 11/20/2020 |
| Termination Date | 11/21/2022 |
| Last Annual Report Date | -- |
| Last Prospectus Date | -- |
| Share Classes | |
| F00001634B | -- |
| F00001634C | -- |
| FHMTWX | -- |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |